InMed Pharmaceuticals
20 hedge funds and large institutions have $4.18M invested in InMed Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
1,930% more capital invested
Capital invested by funds: $206K → $4.18M (+$3.98M)
550% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 2
122% more funds holding
Funds holding: 9 → 20 (+11)
70.46% more ownership
Funds ownership: 10.94% → 81.4% (+70%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$884K |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$882K |
| 3 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$359K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$271K |
| 5 |
UFM
Ursa Fund Management
Danville,
California
|
+$139K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$194K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.1K |
| 3 |
VF
Virtu Financial
New York
|
-$13K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$8.59K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.2K |
INM Hedge Fund Activity: Q2 2026 in Review
20 of the 8,330 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q2 2026, worth a combined $4.18M — up 1,930% from $206K a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new INM positions and 2 closed out — a net gain of 11 holders — while 0 added to existing stakes and 3 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $884K. The largest seller was Sabby Management, cutting an estimated $194K.
- 20 institutional investors held InMed Pharmaceuticals (INM) as of Q2 2026, up from 9 in Q1 2026.
- Funds reported $4.18M of InMed Pharmaceuticals stock for Q2 2026, up 1,930% quarter-over-quarter.
- 13 funds opened new InMed Pharmaceuticals positions in Q2 2026 and 2 closed out, a net change of +11 holders.
- The largest InMed Pharmaceuticals buyer in Q2 2026 was ADAR1 Capital Management, an estimated $884K added.
- The largest InMed Pharmaceuticals seller in Q2 2026 was Sabby Management, an estimated $194K sold.
Based on aggregated 13F filings for Q2 2026.